Business Context and Reporting Period
This Form 10-Q covers Schering-Plough Corporation for the quarterly period ended March 31, 1999. The company is a worldwide research-based pharmaceutical firm engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. Effective January 1, 1999, the company reorganized its internal structure to report as a single segment, consolidating its previous pharmaceuticals and healthcare units.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $2,186 million | $1,908 million |
| Net Income | $539 million | $450 million |
| Diluted EPS | $0.36 | $0.30 |
| Operating Cash Flow | $129 million | $322 million |
| Cash and Equivalents (End) | $1,496 million | $622 million |
| Short-term Debt | $832 million | $558 million |
| Cost of Sales Margin | 19.8% | 19.9% |
| R&D Expense | $262 million | $224 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 15% ($278 million) year-over-year. Excluding foreign currency fluctuations, organic growth was 14%.
- Profitability: Net income rose 20% to $539 million. Income before taxes represented 32.6% of sales, up from 31.3% in 1998.
- Cash Flow Volatility: Operating cash flow decreased significantly to $129 million from $322 million. Management attributes this to the timing of trade purchases rather than operational deterioration.
- Debt and Liquidity: Short-term borrowings increased by $274 million to $832 million, while cash balances grew by $237 million to $1,496 million.
- Shareholder Returns: The company repurchased $153 million of common shares and paid $163 million in dividends during the quarter.
Outlook, Risks, and Management Commentary
Product Performance
Sales of the CLARITIN brand reached $565 million, driving a 15% increase in Allergy & Respiratory sales. Anti-infectives and anticancer products surged 36% due to the U.S. introduction of REBETRON Combination Therapy. Conversely, cardiovascular sales declined 7% due to generic competition for IMDUR and K-DUR.
Year 2000 (Y2K) Readiness
The company estimates a maximum project cost of $95 million, with $46 million incurred as of March 31, 1999. Remediation of IT systems is 99% complete, while non-IT systems are 65% complete. Management expects to finish critical systems by December 31, 1999, but warns that disruptions at third-party vendors (wholesalers, distributors) could materially affect operations.
Legal and Regulatory Risks
- Antitrust Litigation: The company is a defendant in over 160 antitrust actions alleging price-fixing. While a federal class action was settled for $22 million and several state cases settled for non-material amounts, significant actions remain in Alabama, Tennessee, and North Dakota.
- Patent Disputes: Generic challenges to CLARITIN patents by Geneva, Copley, and Teva are ongoing. The company has filed suits alleging willful infringement but notes no assurance of prevailing.
- Environmental: Recorded liabilities for environmental clean-up are not material, though the company remains a potentially responsible party at several Superfund sites.
Investor Verification Checklist
- Verify the sustainability of operating cash flows given the significant Q1 1999 decline attributed to trade purchase timing.
- Monitor the status of CLARITIN patent litigation against Geneva, Copley, and Teva, as these patents are material to the business.
- Assess the progress of Year 2000 remediation for non-IT systems (currently 65% complete) and potential supply chain disruptions from third parties.
- Review the resolution of remaining state antitrust class actions in Alabama, Tennessee, and North Dakota.
- Confirm the impact of generic competition on cardiovascular products (IMDUR, K-DUR) on future margins.